Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Kreuznach – page 11

739 clinical trials in Bad Kreuznach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Kreuznach at a glance
739
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

739 trials in Bad Kreuznach

Open in trial search

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:MZE001
  • Sponsor:Shionogi B.V.

Study comparing treatment with or without tislelizumab for patients with locally advanced rectal cancer to see if surgery can be avoided

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:Rabin Medical Center

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:CatalYm GmbH

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Kreuznach

What the registry says about research in the country

01 Neonatal Care Research

Clinical trials focusing on improving oxygen administration in extremely preterm infants, investigating automated versus manual control systems to enhance respiratory support outcomes.

  • Respiratory Support Management
  • Oxygen Therapy Control
  • Premature Birth Complications

This innovative research aims to evaluate the effectiveness of closed-loop automatic control systems in preventing complications such as ROP, NEC, and BPD while monitoring long-term neurocognitive development in premature babies.

02 Pediatric Intensive Care

Studies examining advanced respiratory support technologies for infants born between 23 and 27 weeks of gestational age, with a focus on optimizing ventilation strategies.

  • Mechanical Ventilation
  • CPAP Management
  • Oxygen Therapy Safety

The research, supported by the German Federal Ministry for Education and Research, explores improvements in neonatal intensive care practices to enhance survival rates and reduce complications.

03 Long-term Developmental Outcomes

Investigation into the long-term effects of oxygen therapy management on neurocognitive development in premature infants, tracked over a 24-month period.

  • Developmental Assessment
  • Mortality Prevention
  • Quality of Life Improvement

This comprehensive study evaluates both immediate medical outcomes and extended developmental progress in extremely preterm infants receiving different oxygen administration methods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.